English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech BioTech (Sci&Research)
这种特效药可能比疫苗更快?君实生物新冠中和抗体计划第二季度进入临床
May 20, 2020 13:24 HKT
Agilex Biolabs Presents the Australian Advantage, including the World's Largest Rebate on Clinical Trial Spend, at BIO Korea 2020
May 20, 2020 16:00 HKT
經申辦方推選,Novotech 榮獲“CRO 領導力大獎”
May 20, 2020 11:00 HKT
经申办方推选,Novotech 荣获“CRO 领导力大奖”
May 20, 2020 11:00 HKT
中国生物制药与康方生物共同开发派安普利单抗联合安罗替尼一线治疗晚期肝癌的临床试验数据获ASCO年会接受呈列
May 19, 2020 17:51 HKT
中國生物製藥與康方生物共同開發派安普利單抗聯合安羅替尼一線治療晚期肝癌的臨床試驗數據獲ASCO年會接受呈列
May 19, 2020 17:50 HKT
Results from Clinical Trials of Penpulimab in Combination with Anlotinib for 1L HCC Co-developed by Sino Biopharmaceutical and Akeso Accepted for Presentation at ASCO Annual Meeting
May 19, 2020 17:50 HKT
开拓药业即将挂牌 明星基石保驾护航
May 18, 2020 16:11 HKT
開拓藥業即將掛牌 明星基石保駕護航
May 18, 2020 16:10 HKT
生物科技股被市场热捧,核心股票如何拣选?
May 11, 2020 11:08 HKT
生物科技股被市場熱捧,核心股票如何揀選?
May 11, 2020 11:07 HKT
Cyber Company to Supply 50M Health "COVI-PASS(TM)"
May 08, 2020 14:30 HKT
商业化变现在即 开拓药业核心产品优势明显
May 08, 2020 10:12 HKT
商業化變現在即 開拓藥業核心產品優勢明顯
May 08, 2020 10:11 HKT
Novotech COVID-19 Clinical Trial Clients Benefit from New Asia-Pacific Fast-Track Review Processes
Apr 28, 2020 19:00 HKT
华领医药宣布Dorzagliatin与恩格列净(一种SGLT-2抑制剂)联合用药临床研究的成功结果
Apr 27, 2020 09:53 HKT
華領醫藥宣佈Dorzagliatin與恩格列淨(一種SGLT-2抑制劑)聯合用藥臨床研究的成功結果
Apr 27, 2020 09:51 HKT
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)
Apr 27, 2020 09:50 HKT
研发强劲无惧竞争 康方生物后发制人底气足
Apr 24, 2020 18:21 HKT
研發強勁無懼競爭 康方生物後發制人底氣足
Apr 24, 2020 18:20 HKT
<< Previous  Next >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: